🔥Telegram İfşa

Well done EDUC8 Network PhD students #himanichand Eleonora #michelaleoni #valeriaporcheddu Sarah Scatigna flora peyvandi Jan Voorberg @DesmazesLacroix #12bic

ABSTRACT BOOK OF 12th BIC International Conference - 2023 - Haemophilia onlinelibrary.wiley.com/doi/abs/10.111…

Dr. Andrea Artoni discusses evidence from clinical trials on #caplacizumab in #ttp at the #ECTH2023 Congress Policlinico di Milano

The main concern about the rebalancing agents that are being developed as #hemophilia treatments is the risk of thrombosis. Based on cases reported so far the risk is Fitusiran>Concizumab>Marstacimab>SerpinPC. Is the risk generic or is there a differentiation between the agents?

Explore haemophilia care's past, present, and future in this special module with Cedric Hermans, MD, FRCP (Lon, Edin), PhD and the EAHAD founding member Professor Pier Mannuccio Mannucci, from his pivotal encounter with Judith Pool to the groundbreaking cryoprecipitation principle 🎥academy.eahad.org/eahad/2023/e-l…

#Gene therapy in #HA of Biomarin has been approved in Italy. Now we are starting another important process on patients education. At Milan #Angelo Bianchi Bonomi ,as a Hub centre, we have started to #talk to #patients deciding what should be done for the benefit of patients

“It will have a major impact on all our lives. Not in 10 years, but in 1 to 3 years, max.” - Michael Makris on AI.

Dr @RobertaGualtie6 from the Angelo Bianchi Bonomi center proposed a telemedicine system using AI for joint bleeding in patients with Hemophilia. EAHAD #eahad2024

Flora Peyvandi invited the audience at EAHAD 2023 to attend next year's meeting which will be held at the start of February in Milan.

🏥 Il Policlinico di Milano è stato scelto come centro hub per la somministrazione della #TerapiaGenica per l'#Emofilia A grave. 🩸 L'ospedale ha una lunga esperienza nel trattamento dell'emofilia e dispone di un team multidisciplinare per monitorare i pazienti. osservatorioterapieavanzate.it/terapie-approv…

The distinctive feature of the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center ISTH #isth2019 #isth2024 Syna Miri

150 hours of half-life of Inno8 The first #oral bispecific nanobodies made by Novo Nordisk a#ISTH2024 highlight

It was a pleasure working with the entire PUP-SWITCH study group. I learned so many things in the making of this project that my PhD revolved around. flora peyvandi Mannucci P M Frits Rosendaal

10-15% of iTTP do not respond to rituximab. Targeting plasma cells can be promising. In this study, durable responses to bortezomib were registered in about 60% of multi-refractory iTTP patients, with mild-to-moderate toxicities. The occurrence of late responses (i.e., after 30

🩸 Switching FVIII in Hemophilia A: Is it Safe? In PUP-SWITCH, just 1 of 87 patients developed inhibitors after switching from plasma-derived to recombinant FVIII post-50 exposure days (1.15%). Findings support safe switching in severe hemophilia A care. Syna Miri Frits Rosendaal

Great talk by Omid Seidizadeh at #eahad2025 on the prevalence of VWD confirming the issue of gross underdiagnosis.

Congratulations to the #EAHAD Lifetime Achievement Award 2025 winner David Lillicrap. #EAHAD2025 #EAHADCongress

Congratulations to Michael Makris on his well deserved #EAHAD Honorary Membership induction. #EAHAD2025 #EAHADCongress

Our editorial on #hemophilia treatments and the paradox of choice is now available in the journal Research and Practice in Thrombosis and Haemostasis. RPTH

🚨 CRISPR's hidden danger: New Nature Communication from genome editing safety experts Toni Cathomen, Carla Fuster García and Clotilde Aussel reveals concerns about "precision" enhancers! ⚠️ It's beyond off-target effects and possibly a worse problem: The field has been focused